Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Therapeutics Inc (NQ: APLT )

9.090 +0.250 (+2.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Applied Therapeutics Inc

< Previous 1 2 Next >
Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Participate in Upcoming Investor Conferences
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Second Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Added to Russell 3000® Index
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Inc. (NASDAQ: APLT) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Applied Therapeutics Reports First Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Inc. (NASDAQ: APLT) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Applied Therapeutics Announces $100 Million Private Placement
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Third Quarter 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the UBS Biopharma Conference 2023
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Second Quarter 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Society
From Applied Therapeutics
Via GlobeNewswire
Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports First Quarter 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity
From Applied Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.